Management of canine atopic dermatitis using the plant extract PYM00217: a randomized, double‐blind, placebo‐controlled clinical study

Abstract

This study evaluated PYM00217, a proprietary blend of plant extracts, in the management of canine atopic dermatitis (AD). One hundred and twenty dogs were diagnosed with perennial AD on the basis of history, clinical signs, a positive test for perennial allergens and elimination of other dermatoses. Exclusion criteria included antimicrobials within 7 days, antihistamines within 14 days, oral/topical glucocorticoids or ciclosporin within 28 days, and parenteral glucocorticoids, essential fatty acids or immunotherapy within 56 days. Flea control, shampoos and ear cleaners were permitted. Dogs with a minimum canine atopic dermatitis extent and severity index (CADESI) of 25 were randomly allocated to receive PYM00217 (100, 200 or 400 mg kg-1 day-1) or placebo for 12 weeks. The mean reductions in CADESI (intention-to-treat population) were 3.9% (placebo; n=29), 4.4% (100 mg kg-1 day-1; n=30), 23.4% (200 mg kg-1 day-1; n=29) and 8.5% (400 mg kg-1 day-1; n=29). The reduction in the 200 mg kg-1 day-1 group was significant (P<0.01). For dogs with a baseline CADESI>or=50, the mean changes were +10.6% (placebo; n=12), +0.6% (100 mg kg-1 day-1; n=14), -29.3% (200 mg kg-1 day-1; n=14) and -3.4% (400 mg kg-1 day-1; n=15). The 200 mg kg-1 day-1 dose was significantly more effective than placebo (P=0.038). No serious adverse effects were reported. Minor adverse effects seen in 10% (placebo and 100 mg kg-1 day-1), 24% (200 mg kg-1 day-1) and 42% (400 mg kg-1 day-1) of cases were mainly minor gastrointestinal disorders and only five cases required cessation of dosing. Two dogs (one in each of the 100 mg kg-1 day-1 and 200 mg kg-1 day-1 groups) refused to eat the medicated food. In conclusion, PYM00217 at 200 mg kg-1 appears to be an effective, palatable and well-tolerated treatment for canine AD.

Evidence‐based veterinary dermatology: a systematic review of interventions for treatment ofPseudomonasotitis in dogs

“…Ideally, concomitant treatments should only be allowed in controlled trials that are sufficiently rigorous to prevent skewed application in a particular group. In a recent RCT for canine atopic dermatitis, an effective randomization and blinding procedure ensured that a variety of concomitant therapies were applied evenly across four treatment groups 29 . In this review of the nine trials in spontaneous cases, only two 21,23 described underlying conditions and only one 21 allowed and discussed concomitant therapies.…”

“…In a recent RCT for canine atopic dermatitis, an effective randomization and blinding procedure ensured that a variety of concomitant therapies were applied evenly across four treatment groups. 29 In this review of the nine trials in spontaneous cases, only two 21,23 described underlying conditions and only one 21 allowed and discussed concomitant therapies. The remaining trial evaluated treatment of experimentally induced cases, 25 which would not be expected to have any underlying conditions.…”

Topical application of Rehmannia glutinosa extract inhibits mite allergen-induced atopic dermatitis in NC/Nga mice

“…In addition, RGAE has been shown to inhibit both compound 48/80-induced systemic allergic and passive cutaneous anaphylaxis (PCA) reactions, two typical models of immediate-type allergic reaction (Kim et al, 1998). In a veterinary study, a mixture of plant extracts (Rehmannia glutinosa, Paeonia lactiflora and Glycyrrhiza uralensis) reduced erythema and pruritus in canine AD (Ferguson et al, 2006). Chemically, Rehmannia glutinosa was found to contain iridoid glycosides such as catalpol, aucubin and ajugol (Oshio and Inouye, 1982).…”

Tepoxalin reduces pruritus and modified CADESI‐01 scores in dogs with atopic dermatitis: a prospective, randomized, double‐blinded, placebo‐controlled, cross‐over study

“…4,5 Allergen avoidance is the logical way to manage CAD, 6 but as this is frequently impractical or ineffective, alternative management regimes are often necessary. These include allergen-specific immunotherapy (ASIT), 7-9 glucocorticoids, 10 ciclosporin, [11][12][13][14][15] antihistamines, [16][17][18] essential fatty acids [19][20][21][22][23][24][25] and Chinese herbal products 26,27 employed alone or in combination. The use of other anti-inflammatory drugs such as pentoxifylline, 28 the prostaglandin E 1 (PGE 1 ) analogue misoprostol and leucotriene inhibitors, [29][30][31][32] recombinant interferon-gamma 33 and topical treatments such as capsaicin 34 and tacrolimus 35 has also been reported.…”